高压氧治疗新型冠状病毒肺炎后遗症患者的探索性研究

注册号:

Registration number:

ChiCTR2400082032 

最近更新日期:

Date of Last Refreshed on:

2024-03-19 14:49:13 

注册时间:

Date of Registration:

2024-03-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

高压氧治疗新型冠状病毒肺炎后遗症患者的探索性研究

Public title:

Exploratory Study of Hyperbaric Oxygen Therapy for Post-acute Sequelae of SARS-CoV-2 Infection

注册题目简写:

English Acronym:

研究课题的正式科学名称:

高压氧治疗新型冠状病毒肺炎后遗症患者的探索性研究

Scientific title:

Exploratory Study of Hyperbaric Oxygen Therapy for Post-acute Sequelae of SARS-CoV-2 Infection

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张雪飞 

研究负责人:

童朝晖 

Applicant:

Zhang Xuefei 

Study leader:

Tong Zhaohui 

申请注册联系人电话:

Applicant telephone:

+86 151 5776 1135

研究负责人电话:

Study leader's
telephone:

+86 139 1093 0309

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1270802679@qq.com

研究负责人电子邮件:

Study leader's E-mail:

tongzhaohuicy@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市工体南路8号

研究负责人通讯地址:

北京市工体南路8号首都医科大学附属北京朝阳医院

Applicant address:

8 Worker Stadium Road South, Beijing, China

Study leader's address:

8 Worker Stadium Road South, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京朝阳医院

Applicant's institution:

Beijing Chaoyang Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京朝阳医院

Affiliation of the Leader:

Beijing Chaoyang Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-科-80

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京朝阳医院伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing Chaoyang Hospital Affiliated to Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-02-05 00:00:00

伦理委员会联系人:

吕亚丽

Contact Name of the ethic committee:

Lyu Yali

伦理委员会联系地址:

北京朝阳区工人体育场南路8号

Contact Address of the ethic committee:

8 Worker Stadium Road South, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8523 1484

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京朝阳医院

Primary sponsor:

Beijing Chaoyang Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市工体南路8号

Primary sponsor's address:

8 Worker Stadium Road South, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京朝阳医院

具体地址:

工体南路8号

Institution
hospital:

Beijing Chaoyang Hospital

Address:

8 Worker Stadium Road South

经费或物资来源:

科技部重大专项

Source(s) of funding:

Major projects of the ministry of science and technology

研究疾病:

新型冠状病毒肺炎后遗症  

Target disease:

Post-acute Sequelae of SARS-CoV-2 Infection

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

本研究的主要目的是评估高压氧治疗对于已治愈的新冠肺炎患者在康复期间仍然出现的长新冠症状的改善效果。考虑到一部分新冠肺炎康复患者在病毒清除后仍面临多种持续性症状,如呼吸困难、疲劳和认知功能障碍等,本研究致力于探索高压氧治疗是否能够有效改善这些长期症状,从而提升患者的生活质量。通过科学的研究设计和严谨的数据分析,旨在为新冠康复期患者的后续治疗提供有效的临床证据和指导。  

Objectives of Study:

The main objective of this study is to evaluate the efficacy of hyperbaric oxygen therapy in improving long-term symptoms persisting during the recovery phase in patients who have recovered from COVID-19. Considering that a subset of COVID-19 recovery patients still faces various persistent symptoms post-virus clearance, such as difficulty breathing, fatigue, and cognitive dysfunction, this study aims to explore whether hyperbaric oxygen therapy can effectively alleviate these long-term symptoms, thereby enhancing the quality of life for patients. Through scientific research design and rigorous data analysis, the study seeks to provide effective clinical evidence and guidance for subsequent treatment of COVID-19 recovery patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.未满18岁; 2.患有慢性阻塞性肺疾病、气胸、胸膜炎、耳蜗炎或鼓室炎、癫痫者; 3.目前处于急性呼吸道感染者;患有危及生命的心血管疾病,如未经控制的高血压、心肌梗塞等; 4.患有精神疾病者;患有幽闭恐惧症者; 5.妊娠或哺乳期妇女; 6.拒绝参加定期评估;

Exclusion criteria:

1. Under 18 years of age; 2. Suffering from chronic obstructive pulmonary disease (COPD), pneumothorax, pleurisy, labyrinthitis or otitis media, epilepsy; 3. Currently experiencing acute respiratory tract infections; Suffering from life-threatening cardiovascular diseases, such as uncontrolled hypertension, myocardial infarction, etc.; 4. Suffering from mental illness; Suffering from claustrophobia; 5. Pregnant or lactating women; 6. Refusing to participate in regular assessments.

研究实施时间:

Study execute time:

From 2024-01-01 00:00:00 To 2025-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-03-25 00:00:00 To 2025-01-01 00:00:00

干预措施:

Interventions:

组别:

高压氧治疗组

样本量:

20

Group:

Hyperbaric Oxygen Therapy Group

Sample size:

干预措施:

高压氧治疗组将接受为期2周及以上的治疗,每周5次,全程2小时,使用2 ATA。样本量未确定,由于这种干预治疗措施相对较新,目前尚无针对新冠康复后仍遭遇呼吸困难患者的相关研究。因此,本研究计划首先拟开展一项预实验,拟各组分别纳入20例受试者,观察受试者症状改善的情况。基于预实验的结果,我们将进一步计算所需的样本量,以进行更深入的研究。

干预措施代码:

Intervention:

The hyperbaric oxygen treatment group will receive treatment for 2 weeks or more, 5 times per week for 2 hours, using 2 ATA.

Intervention code:

组别:

常规氧疗组

样本量:

20

Group:

Conventional Oxygen Therapy Group

Sample size:

干预措施:

根据临床医生建议及自身情况,采取常规氧疗,如鼻导管氧疗等

干预措施代码:

Intervention:

Conventional e oxygen therapy, such as nasal catheter oxygen therapy, should be taken according to the advice of clinicians and their own conditions

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京朝阳医院 

单位级别:

三甲 

Institution
hospital:

Beijing Chaoyang Hospital, Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京潞河医院 

单位级别:

三级 

Institution
hospital:

Beijing h Hospital, Capital Medical University

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京市顺义区医院 

单位级别:

三级 

Institution
hospital:

Beijing Shunyi Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北大医疗康复医院 

单位级别:

三级 

Institution
hospital:

Peking University Care Rehabilitation Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

民航总医院 

单位级别:

三级 

Institution
hospital:

Civil Aviation General Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军总医院 

单位级别:

三甲 

Institution
hospital:

Chinese PLA General Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

机体功能障碍改善情况

指标类型:

主要指标

Outcome:

Improvement in Organ Dysfunction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高压氧改善新冠后遗症患者机体功能障碍相关的免疫学特点

指标类型:

次要指标

Outcome:

Improvement in Immune Profiles Associated with Organ Dysfunction in Post-COVID-19 Patients Treated with Hyperbaric Oxygen Therapy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高压氧改善新冠后遗症患者机体功能障碍相关的多组学特点

指标类型:

次要指标

Outcome:

The Multiomics Characteristics Associated with Improvement of Organ Dysfunction in Post-COVID-19 Patients Treated with Hyperbaric Oxygen

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

实验室化验检查

指标类型:

主要指标

Outcome:

Laboratory test

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胸部高分辨CT

指标类型:

次要指标

Outcome:

High-resolution CT of the chest

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Not stated

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not stated

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过填写病例记录表(CRF)采集数据,通过录入电子采集和管理系统(EDC)统一管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data were collected through CRF and managed by inputting the data into the EDC.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-03-19 14:48:33